Unlabelled: Serbian oncologists benefited of a short training in French structures as observer between 2003 and 2007. To this day, there has been yet no study on the professional feedback of this kind of training for foreigner doctors. Our aim was to evaluate the satisfaction of the participants and thereafter to analyse their needs.
Material And Methods: Survey by auto questionnaires sent to the participants oncologists.
Results: On 60 oncologists, 40 answered. On all the oncologists interviewed, 90% thought that the knowledge was easily accessible and is still useful. Sixty per cent said they introduced new protocols; 92.3% wished they could have another training. Compared to their own practise in Serbia, 97% think there is a employee in charge of administrative questions that set the doctors free to do something else.
Discussion: To optimise these training's, basic knowledge of French and well-targeted expectations are essential. To improve professional practise of oncologists, the answers go to a best internal communication and the establishment of a politic of education for doctors and the rest of the personal in oncology services.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/bdc.2009.0918 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Attitudes toward Death among Health Care Professionals in the Balkan Region.
Curr Oncol
June 2024
University of Belgrade, Faculty of Medicine, 11000 Belgrade, Serbia.
: Death is an unavoidable experience in any person's life and affects not only the dying person but also their caregivers. The dying process has been displaced from homes to health care facilities in the majority of cases. Facing death and dying has become an everyday life of health care professionals (HCP), especially in palliative care (PC) settings.
View Article and Find Full Text PDFAvailability of technology for managing cancer patients in the Southeast European (SEE) region.
Clin Transl Radiat Oncol
May 2022
Bulgarian National Cancer Registry, Bulgaria.
Background: The Southeast European (SEE) region of 10 countries and about 43 million people differs from Western Europe in that most SEE countries lack active cancer registries and have fewer diagnostic imaging devices and radiotherapy (RT) units. The main objective of this research is to initiate a common platform for gathering SEE regional cancer data from the ground up to help these countries develop common cancer management strategies.
Methods: To obtain detailed on-the-ground information, we developed separate questionnaires for two SEE groups: a) ONCO - oncologists regarding cancer treatment modalities and the availability of diagnostic imaging and radiotherapy equipment; and b) REG - national radiation protection and safety regulatory bodies regarding diagnostic imaging and radiotherapy equipment in SEE facilities.
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
Eur J Heart Fail
December 2020
Institute of Experimental Cardiology, Heidelberg University Hospital, Heidelberg, Germany.
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a growing body of experimental and clinical evidence reveals numerous commonalities in the biology underlying both pathologies. Inflammation emerges as a common hallmark for both diseases as it contributes to the initiation and progression of both HF and cancer.
View Article and Find Full Text PDFBaseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Eur J Heart Fail
November 2020
Cardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, MO, USA.
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
View Article and Find Full Text PDFSerbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE.
J BUON
August 2019
Clinic for Medical Oncology, Institute of Oncology of Vojvodina, Sremska Kamenica, Serbia.
Even though surgery is the primary treatment of operable breast cancer, it has been known for decades that the administration of postoperative adjuvant or preoperative neoadjuvant therapy is extremely important. Indications for neodjuvant therapy administration have been expanded over the years, and nowadays this kind of treatment represents an inevitable option in early breast cancer treatment. The NeoPULSE project, which gathered a group of experts in the field of breast cancer from five Serbian university centres, was formed with the aim to define optimal breast cancer diagnosis, indications for neoadjuvant therapy, therapeutic combinations in relation to molecular/biological parameters of breast cancer, as well as the treatment after neoadjuvant therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!